Huntington's disease treatment market by drug type (approved drugs, off-label drugs), by age (under 50, over 50), by distribution channel (hospital pharmacies, drugstores and retail pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031 “The global Huntington's disease treatment industry was valued at $315.2 million in 2021 in 2021 and is projected to reach 707 according to the report $.5 trillion by 2031, registering a CAGR of 8.4% from 2022 to 2031. The report offers explicit analysis of changing market trends, major segments, major investment pockets, value chains, competitive scenarios and regional panoramas.
Download Sample
Report: https://www.alliedmarketresearch.com/request-sample/17971
Growth drivers-
Increasing population and rising demand for advanced types
of drugs to control symptoms associated with Huntington's disease drive the
growth of the global Huntington's disease treatment market. On the other hand,
some complications associated with the treatment of Huntington's disease impede
growth to some extent. However, the increased demand for advanced disease
treatments has created lucrative opportunities in the industry.
Impact of Covid-19 on
Huntington's disease treatment market-
Most hospitals around the world have been restructured to
increase hospital capacity for patients diagnosed with Covid-19, with
non-essential procedures potentially delayed due to the rapid increase in
Covid-19 cases. Furthermore, other factors responsible for the market impact
include limited healthcare availability and shortage of healthcare personnel
which has negatively impacted the global Huntington's disease treatment market.
The segment of approved drugs takes the lion's share.
By drug type, the approved drugs segment contributed more
than four-fifths of the global Huntington's disease treatment market share in
2021 and is projected to lead the market by 2031. The same segment is also
expected to show the fastest CAGR of 8.5% between 2022 and 2031. This is due to
the growing demand for effective treatments and the rapid development of other
disease-modifying drugs. Under-50s segment to dominate by 2031-
By age, the under 50 segment captured more than half of the
global Huntington's disease treatment market share in 2021 and is expected to
maintain its dominance by 2031. The same segment is also projected to show the
highest CAGR rapid 8.6% between 2022 and 2021 2031, due to a higher incidence
of the disease in this age group. For the purchase
Speak to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/17971
North America was
obtained more in 2021-
According to the Region, North America has maintained the
greatest participation in 2021, generating more than two fifths of the world
market of the treatment of diseases in Huntington. This is attributed to
technological progress in the treatment of Huntington disease and the presence
of key actors throughout the region. The Asia-Pacific region, concurrently,
would quote the fastest CAGR of 9.2% over the entire forecast period. The
increase in the assisted population, the development of health infrastructure
and the increase in investment projects in the province drive the growth of the
market. Industry Leaders-
Key Players-
Bausch Health Companies Inc.
Eli Lilly And Company
Hikma Pharmaceuticals PLC
Lupin
Medesis pharma SA
Annexon Biosciences
Vaccinex, Inc.
Mitochon Pharmaceuticals
Neurocrine bioscience Inc.
Dr.Reddy's Laboratories Ltd
Novartis
PTC Therapeutics, Inc.
SOM Biotech
Sun Pharmaceuticals
Teva Pharmaceuticals Industries Ltd.
UniQure
Read More- https://www.alliedmarketresearch.com/huntington%E2%80%99s-disease-treatment-market-A17522?
No comments:
Post a Comment